Sugi Predict

Sugi Predict / Compounds / SCHEMBL19617430

SCHEMBL19617430

SCHEMBL19617430

CCOC(=O)CCC(C)N(CC(=O)OCC)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.50
▸ MAPT P10636 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ALOX5 P09917 1/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNB4 P30926 1/20 0.43
▸ CHRNA3 P32297 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ LTA4H P09960 1/20 0.41
▸ PIN1 Q13526 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ BCHE P06276 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477616 0.87 ALOX5 (0.51) TP53ALOX5SMN1; SMN2LTA4H
SCHEMBL735309 0.86 TP53 (0.52) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL735308 0.86 TP53 (0.52) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL22608475 0.86 TP53 (0.49) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL22608474 0.86 TP53 (0.49) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL22608472 0.86 TP53 (0.49) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL891284 0.83 TP53 (0.52) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL6598581 0.81 TP53 (0.49) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL28400999 0.80 TP53 (0.47) TP53MAPTALDH1A1LMNAPOLB
SCHEMBL28401001 0.80 TP53 (0.47) TP53MAPTALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-04 — — US disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
CN-118480029-A 2-Aminopyrimidine compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-08-13 — — CN disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
EP-3710439-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-02-15 — — EP disclosed
US-11267812-B2 KRAS G12C inhibitors Mirati Therapeutics, Inc. (US) 2022-03-08 — — US disclosed
EP-3458445-B1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2021-02-17 — — EP disclosed
EP-3710439-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2020-09-23 — — EP disclosed
US-20200262837-A1 KRAS G12C INHIBITORS ARRAY BIOPHARMA INC. 2020-08-20 — — US disclosed
US-10689377-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-06-23 — — US disclosed
US-10633381-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2020-04-28 — — US disclosed
US-20190144444-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2019-05-16 — — US disclosed
EP-3458445-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2019-03-27 — — EP disclosed
US-10125134-B2 KRas G12C inhibitors Mirati Therapeutics, Inc. (US) 2018-11-13 — — US disclosed
US-20180072723-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. 2018-03-15 — — US disclosed
WO-2017201161-A1 KRAS G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2017-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144444-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-10633381-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-20200262837-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-11267812-B2 KRAS G12C inhibitors KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-10125134-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-10689377-B2 KRas G12C inhibitors KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS TP53 4/4885MAPT 3384/4885ALDH1A1 3283/4885
US-20180072723-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS TP53 5/4885MAPT 3928/4885ALDH1A1 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.